Clinical trial
Efficacy and Safety of DHEA for Myotonic Dystrophy
NCT00167609 · University of Versailles, Other · Completed
Key facts
| NCT number | NCT00167609 |
|---|---|
| Title | Efficacy and Safety of DHEA for Myotonic Dystrophy |
| Official title | Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy |
| Lead sponsor | University of Versailles, Other |
| Collaborators | Association Française contre les Myopathies (AFM), Paris Assistance Publique - Hôpitaux de Paris |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Myotonic Dystrophy |
| Intervention type | Drug |
| Interventions | dehydroepiandrosterone 100 and 400 mg |
| Enrollment | 75 |
| Start date | Nov 1, 2004 |
| Completion | Dec 1, 2006 |
| First posted | Sep 14, 2005 |
| Last update posted | Apr 6, 2010 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: